Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.
The Company’s three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and INGREZZA™, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome.
Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine’s chemists, pharmacologists, and biologists strive to create new solutions to unmet medical problems.
Type
Public
HQ
San Diego, US
Founded
1992
Size (employees)
400 (est)
Neurocrine Biosciences was founded in 1992 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Neurocrine Biosciences

Kevin Gorman

Kevin Gorman

CEO
Tim Coughlin

Tim Coughlin

CFO
David-Alexandre Gros

David-Alexandre Gros

President and COO
Eric Benevich

Eric Benevich

Chief Commercial Officer
Julie Cooke

Julie Cooke

Chief People Officer

Neurocrine Biosciences Office Locations

Neurocrine Biosciences has an office in San Diego
San Diego, US (HQ)
12780 El Camino Real
Show all (1)
Report incorrect company information

Neurocrine Biosciences Financials and Metrics

Neurocrine Biosciences Financials

Neurocrine Biosciences's revenue was reported to be $15 m in FY, 2016 which is a 24.1% decrease from the previous period.
USD

Revenue (Q1, 2018)

71.1 m

Gross profit (Q1, 2018)

70.1 m

Gross profit margin (Q1, 2018), %

98.7%

Net income (Q1, 2018)

(41.8 m)

EBIT (Q1, 2018)

(37.4 m)

Market capitalization (22-Jun-2018)

9.2 b

Closing share price (22-Jun-2018)

101.8

Cash (31-Mar-2018)

175.3 m
Neurocrine Biosciences's current market capitalization is $9.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.9 m19.8 m15 m

Revenue growth, %

(100%)(24%)

General and administrative expense

13.3 m18 m32.5 m68.1 m

R&D expense

39.2 m46.4 m81.5 m94.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

19.8 m15 m71.1 m

Cost of goods sold

950 k

Gross profit

70.1 m

Gross profit Margin, %

99%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

44.8 m31 m74.2 m83.3 m

Current Assets

148.5 m198.2 m384.1 m310.4 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

37.4 m29 m170.3 m132.1 m66.4 m115.3 m86.2 m99.8 m64.1 m175.3 m

Accounts Receivable

44.6 m

Current Assets

197.6 m183.9 m405 m389.4 m382.8 m401 m392 m357.9 m239.5 m513.7 m

PP&E

2.2 m2.3 m2.5 m2.8 m2.9 m3.9 m5.8 m6.2 m7.1 m11.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.1 m)(60.5 m)(88.9 m)(141.1 m)

Depreciation and Amortization

671 k827 k1 m1.5 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(13.4 m)(15.9 m)(1.2 m)(24 m)(34.4 m)(19.3 m)(40.3 m)(36.9 m)(78.3 m)(41.8 m)

Depreciation and Amortization

786 k

Accounts Payable

846 k900 k1.3 m1 m1.2 m2.1 m1.8 m1.7 m852 k(7.9 m)

Cash From Operating Activities

(38.5 m)
USDY, 2018

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information

Neurocrine Biosciences News and Updates

Report incorrect company information